Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Drug Profile

Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Alternative Names: CDK4 inhibitors - Onconova; ON 108110; ON 108600; ON-123300; ON-150030

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onconova Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Onconova Therapeutics
  • Class Pyrimidines; Thiazines
  • Mechanism of Action Casein kinase II inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; NUAK1 protein inhibitors; PIM3 protein inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Protein-serine-threonine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Colorectal cancer
  • Research Breast cancer
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Apr 2017 Preclinical trials in Acute myeloid leukaemia in USA
  • 04 Apr 2017 Pharmacodynamics data from a preclincial study in Cancer presented at the 108th Annual Meeting of American Association of Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top